title: Evaluation of prostate-specific antigen response following cessation of abiraterone acetate: is there evidence for a withdrawal syndrome?
authors.affiliation: Department of Medical Oncology, British Columbia Cancer Agency, Vancouver, BC, Canada. Electronic address: arun.azad@bccancer.bc.ca.
authors.forename: Arun A
authors.initials: AA
authors.lastname: Azad
authors.affiliation: Department of Medical Oncology, British Columbia Cancer Agency, Vancouver, BC, Canada.
authors.forename: Bernhard J
authors.initials: BJ
authors.lastname: Eigl
mesh_terms: D000069501:Abiraterone Acetate; D000730:Androstadienes / Q000008:administration & dosage / Q000009:adverse effects*; D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage / Q000009:adverse effects*; D018450:Disease Progression; D004334:Drug Administration Schedule; D006801:Humans; D007610:Kallikreins / Q000097:blood*; D008297:Male; D017430:Prostate-Specific Antigen / Q000097:blood*; D064129:Prostatic Neoplasms, Castration-Resistant / Q000097:blood / Q000188:drug therapy* / Q000473:pathology; D012189:Retrospective Studies; D012307:Risk Factors; D013375:Substance Withdrawal Syndrome / Q000097:blood / Q000175:diagnosis / Q000209:etiology*; D013997:Time Factors
chemical_list: D000730:Androstadienes; D018931:Antineoplastic Agents, Hormonal; C549870:KLK3 protein, human; D007610:Kallikreins; D017430:Prostate-Specific Antigen; D000069501:Abiraterone Acetate